RxDoctor Payments Data

Mary Snow, APRN

Women's Health · Lincoln, NENPI 1023004371

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Astellas Pharma US Inc at 45.7% of the total.

$944in general payments, 2019–2025

Across 49 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$431
  • AbbVie$258
  • Biohaven Pharmaceutical Holding Company Ltd.$61
  • Bayer$47
  • Mayne Pharma Commercial LLC$33
  • Avion Pharmaceuticals$20
  • plus $93 from 6 others

What the payments were for

  • Food & beverage$944100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$944 in reported general payments places this provider in the 60th percentile of 60 women's health providers in Nebraska.

See all women's health providers in Nebraska

Medicare billing

Part B allowed, 2024
$14,495
Medicare patients
198
Services billed
423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol210$8,030
MyrbetriqMirabegron14$6,233
Estradiol (Twice Weekly)Estradiol39$2,495
ValacyclovirValacyclovir Hcl25$1,380
SynthroidLevothyroxine Sodium14$1,334
ProgesteroneProgesterone, Micronized27$1,069
Medroxyprogesterone Acetate48$825
Levothyroxine Sodium74$478
Escitalopram Oxalate26$455
Alendronate Sodium45$184
Trazodone Hcl11$85
Fluoxetine Hcl11$76
Atorvastatin Calcium12$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$431$6,23314 claims
AbbVieSynthroid$258$1,33414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 60 women's health providers in Nebraska.

Other women's health in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →